Teva Defends Vincristine Discontinuation Decision
Insists It Is Not Responsible For US Shortages
Amid emotive US mainstream media coverage of shortages of the children’s cancer treatment vincristine, Teva insists it is not to blame after discontinuing production of the chemotherapy agent.
You may also be interested in...
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.
The first three FDA approvals for generic fingolimod generics come amid ongoing legal uncertainty over Novartis’ Gilenya blockbuster multiple sclerosis treatment.